Table 5.
Performance of p16/Ki-67 at different cutoffs.
| Cutoff | Endpoint | Sensitivity | Specificity | PPV | NPV | Youden's index | Test positivity |
|---|---|---|---|---|---|---|---|
| p16/Ki-67, ≥2 cells | AIN2 + | 88.8% (80.9–93.8) | 55.4% (48.6–61.9) | 48.7% (41.5–55.9) | 91.2% (84.8–95.2) | 0.44 | 58.9% |
| AIN3 | 91.4% (80.3–96.8) | 48.0% (41.9–54.1) | 27.2% (21.2–34.1) | 96.3% (91.2–98.6) | 0.39 | ||
| p16/Ki-67, ≥5 cells | AIN2 + | 77.6% (68.3–84.8) | 73.2% (66.8–78.8) | 58.0% (49.5–66.1) | 87.2% (81.4–91.5) | 0.51 | 43.2% |
| AIN3 | 91.4% (80.3–96.8) | 67.0% (61.1–72.5) | 37.1% (29.3–45.6) | 97.3% (93.6–99.0) | 0.58 | ||
| p16/Ki-67, ≥50 cells | AIN2 + | 47.7% (38.0–57.5) | 90.6% (85.8–94.0) | 70.8% (58.8–80.7) | 78.4% (72.8–83.1) | 0.38 | 21.8% |
| AIN3 | 67.2% (53.5–78.6) | 87.9% (83.3–91.4) | 54.2% (42.1–65.8) | 92.7% (88.6–95.4) | 0.55 |
AIN1, anal intraepithelial neoplasia grade 1; AIN2, anal intraepithelial neoplasia grade 2; AIN3, anal intraepithelial neoplasia grade 3; NPV, negative predictive value; PPV, positive predictive value.